- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00793234
Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery
Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery: A Dose-Escalating, Multicenter, Randomised, Active- Controlled Open Label Study
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Currently available anticoagulant therapies for the prevention of VTE include low molecular weight heparins, pentasaccharides and vitamin K antagonists, all of which have inherent limitations(1-3).
Improved anticoagulant agents are therefore required(4). A novel antithrombotic agent requires demonstration of both efficacy and safety in relevant populations. Phase II studies are frequently performed in patients undergoing total hip replacement and/or total knee replacement because of the high and well documented incidence of deep vein thrombosis in the absence of adequate thromboprophylaxis(5-7).
In this study, we assess the safety and efficacy of TB-402, a novel antithrombotic agent that partially inhibits factor VIII, in the prevention of VTE in patients undergoing total knee replacement surgery.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
Pleven, Bulgarien, 5800
- SHAT of orthopedics, traumatology and surgery "Sv. Pantaleimon " - Pleven Department of Orthopaedics and Traumatology
-
Plovdiv, Bulgarien, 4002
- Dept. of Orthopedics, UMHAT "Saint George"
-
Rousse, Bulgarien, 7002
- MHAT Rousse
-
Sofia, Bulgarien, 1709
- MHAT "Sveta Anna" AD - Sofia, Clinic of Orthopedics and Traumatology
-
Varna, Bulgarien, 9000
- MHAT "Sv. Anna", Department of Orthopaedics and Traumatology
-
-
-
-
-
Beer - Sheva, Israel, 84101
- Soroka MC
-
Beer-Yaakov, Israel, 70300
- Asaf Harofeh MC
-
Haifa, Israel, 31096
- Rambam MC
-
Jerusalem, Israel, 91031
- Shaare Zedek Mc
-
Kfar Saba, Israel, 44281
- Meir Medical Center (MC)
-
Petach Tikva, Israel, 49100
- Beilinson Hospital
-
Rehovot, Israel, 76100
- Kaplan MC
-
Tel Aviv, Israel, 64239
- Sourasky MC
-
-
-
-
-
Liepāja, Lettland, LV-3400
- Ltd "Liepajas regionala slimnica"
-
Riga, Lettland, LV-1005
- Ltd "Traumatologijas un ortopedijas slimnica"
-
Valmiera, Lettland, LV 4201
- Vidzemes slimnica
-
-
-
-
-
Bydgoszcz, Polen, 85-094
- Szpital Uniwersytecki im. dr. Antoniego Jurasza w Bydgoszczy Klinika Ortopedii i Traumatologii Narządu Ruchu
-
Kraków, Polen, 31-826
- Wojewódzki Szpital Specjalistyczny im. L. Rydygiera w Krakowie, Oddział Kliniczny Ortopedii i Traumatologii Narządu Ruchu
-
Lubuskie, Polen, 20-090
- Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie, Katedra i Klinika Ortopedii Traumatologii i Rehabilitacji
-
Podlaski, Polen, 15-276
- Uniwersytecki Szpital Kliniczny w Białymstoku, Klinika Ortopedii i Traumatologii
-
Warszawa, Polen, 03-242
- Wojewódzki Szpital Bródnowski Samodzielny Publiczny Zakład Opieki Zdrowotnej, Oddział Chirurgii Urazowo-Ortopedycznej i Rehabilitacji
-
-
-
-
-
Bucuresti, Rumänien, 042122
- Spitalul Clinic de Urgenta Sf. Ioan Bucuresti
-
Cluj - Napoca, Rumänien, 400132
- Spitalul Clinic de Urgenta Prof. Dr. Octavian Fodor CLUJ NAPOCA
-
Craiova, Rumänien, 200642
- Spitalul Clinic Judetean de Urgenta Craiova
-
-
-
-
-
Cheliabinsk, Russische Föderation, 454136
- Municipal Healthcare Institution "City Clinical Hospital No. 3"
-
Moscow, Russische Föderation, 111539
- Moscow State Healthcare Institution "City Clinical Hospital No. 15 n.a. O.M. Filatov"
-
Orenburg, Russische Föderation, 460000
- Municipal Healthcare Institution "City Clinical Hospital No. 4"
-
Saint Petersburg, Russische Föderation, 194291
- Federal State Medical Institution: Clinical Hospital #122 named after L.G. Sokolov under the Federal Medical-Biological Agency
-
Saint Petersburg, Russische Föderation, 194354
- Saint Petersburg State Healthcare Institution "Municipal Multi-Speciality Hospital No. 2"
-
Saint Petersburg, Russische Föderation, 197046
- Federal State Institution "Russian Research Institute of Traumatology and Orthopedics n.a. R.R. Vreden under the Federal Authority for Healthcare and Social Development"
-
Saint-Petersburg, Russische Föderation, 193312
- Saint Petersburg State Healthcare Institution "Aleksandrovskaya Hospital"
-
Samara, Russische Föderation, 443095
- State Healthcare Institution "Samara Regional Clinical Hospital n.a. M.I. Kalinin"
-
-
-
-
-
Cherkassy, Ukraine, 18009
- Cherkasska Regional Hospital. Department of Orthopedics and Traumatology.
-
Ivano-Frankivsk, Ukraine, 76008
- Ivano-Frankіvsk Regional Clinical Hospital, Department of ortopedics and traumatology.
-
Odessa, Ukraine, 65025
- Odessa Regional Clinical Hospital, Department of Orthopedics and Traumatology
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Male or female patients aged > 18 and < 80 years old
- Female patients should be post menopausal
- Patients undergoing primary elective total knee replacement surgery
- Written informed consent obtained from the patient (or a legally acceptable representative) prior to inclusion in the study
- Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures
Exclusion Criteria:
- Body weight < 50 kg or > 100 kg
- Patients undergoing a hemiarthroplasty, surface repair or revisionary surgery of the knee
- Confirmed symptomatic deep vein thrombosis or pulmonary embolism within the past year
- Anticipated use of indwelling intrathecal or epidural catheter for more than 4 h after surgery or during the entire study
- Uncontrolled hypertension (SBP>160 mm Hg or DBP > 100 mm Hg)
- History of intracranial or intraocular bleeding. History of gastrointestinal and/or endoscopically verified ulcer disease within the past year
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Aktiver Komparator: 4
|
Enoxaparin 40mg/day sc injection for at least 10 days post-surgery
|
Experimental: 1
0.3 mg/kg TB-402
|
TB-402 administered as single bolus 18-24 post total knee replacement surgery.
|
Experimental: 2
0.6 mg/kg TB-402
|
TB-402 administered as single bolus 18-24 post total knee replacement surgery.
|
Experimental: 3
1.2 mg/kg TB-402
|
TB-402 administered as single bolus 18-24 post total knee replacement surgery.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
The occurrence of total bleeding defined as major and/or clinically relevant non-major bleeding events, from randomisation until the end of the study.
Zeitfenster: All visists from randomization to end of study
|
All visists from randomization to end of study
|
Composite of the occurrence of asymptomatic DVT as detected by bilateral venography and symptomatic VTE, i.e. DVT or fatal or non-fatal PE.
Zeitfenster: Prior to hospital discharge Day 7-11
|
Prior to hospital discharge Day 7-11
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Incidence of major bleeding events
Zeitfenster: All visists from randomization to end of study
|
All visists from randomization to end of study
|
Incidence of clinically significant non-major bleeding events
Zeitfenster: All visits from randomization to end of study
|
All visits from randomization to end of study
|
Incidence of minor bleeding events
Zeitfenster: All visits from randomization to end of study
|
All visits from randomization to end of study
|
Incidence of all cause mortality
Zeitfenster: All visits from randomization to end of study
|
All visits from randomization to end of study
|
Incidence of adverse events
Zeitfenster: All visists from randomization to end of study
|
All visists from randomization to end of study
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- TB-402-004
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur TB-402
-
ThromboGenicsBioInvent International ABAbgeschlossen
-
ThromboGenicsBioInvent International ABAbgeschlossen
-
University of OxfordCrucell Holland BV; University of Birmingham; Emergent BioSolutions; AerasAbgeschlossenTuberkuloseVereinigtes Königreich
-
ThromboGenicsBioInvent International ABAbgeschlossen
-
Reata, a wholly owned subsidiary of BiogenZurückgezogen
-
Reata, a wholly owned subsidiary of BiogenBeendetLeber erkrankungVereinigte Staaten
-
Kyowa Kirin Co., Ltd.BeendetTyp 2 Diabetes | Chronisches NierenleidenJapan
-
M.D. Anderson Cancer CenterReata Pharmaceuticals, Inc.AbgeschlossenSolide Tumore | Lymphatische MalignomeVereinigte Staaten
-
Kyowa Kirin Co., Ltd.AbgeschlossenTyp 2 Diabetes | Chronisches NierenleidenJapan
-
Reata, a wholly owned subsidiary of BiogenAbgeschlossenDiabetische NephropathieVereinigte Staaten